BioArctic AB (publ) (BIOA-B) - Total Liabilities
Based on the latest financial reports, BioArctic AB (publ) (BIOA-B) has total liabilities worth Skr631.81 Million SEK (≈ $67.99 Million USD) as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore BIOA-B cash flow conversion to assess how effectively this company generates cash.
BioArctic AB (publ) - Total Liabilities Trend (2015–2024)
This chart illustrates how BioArctic AB (publ)'s total liabilities have evolved over time, based on quarterly financial data. Check BIOA-B financial resilience to evaluate the company's liquid asset resilience ratio.
BioArctic AB (publ) Competitors by Total Liabilities
The table below lists competitors of BioArctic AB (publ) ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
ViTrox Corporation Bhd
KLSE:0097
|
Malaysia | RM410.88 Million |
|
Zhuhai Bojay Electronics Co Ltd
SHE:002975
|
China | CN¥886.78 Million |
|
Konecranes Plc
HE:KCR
|
Finland | €2.45 Billion |
|
Brightstar Lottery PLC
NYSE:BRSL
|
USA | $7.93 Billion |
|
Energisa S.A
SA:ENGI3
|
Brazil | R$60.22 Billion |
|
Hyosung Corp
KO:004800
|
Korea | ₩2.24 Trillion |
|
Sai Gon Ha Noi Commercial Joint Stock Bank
VN:SHB
|
Vietnam | ₫824.57 Trillion |
Liability Composition Analysis (2015–2024)
This chart breaks down BioArctic AB (publ)'s total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see BIOA-B market cap.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 4.18 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | 1.84 | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.32 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.24 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how BioArctic AB (publ)'s debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for BioArctic AB (publ) (2015–2024)
The table below shows the annual total liabilities of BioArctic AB (publ) from 2015 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | Skr216.74 Million ≈ $23.32 Million |
+55.37% |
| 2023-12-31 | Skr139.50 Million ≈ $15.01 Million |
+93.58% |
| 2022-12-31 | Skr72.06 Million ≈ $7.76 Million |
-33.92% |
| 2021-12-31 | Skr109.05 Million ≈ $11.74 Million |
-23.75% |
| 2020-12-31 | Skr143.01 Million ≈ $15.39 Million |
-31.52% |
| 2019-12-31 | Skr208.84 Million ≈ $22.47 Million |
-44.36% |
| 2018-12-31 | Skr375.31 Million ≈ $40.39 Million |
-25.59% |
| 2017-12-31 | Skr504.35 Million ≈ $54.28 Million |
-22.07% |
| 2016-12-31 | Skr647.22 Million ≈ $69.65 Million |
+2735.43% |
| 2015-12-31 | Skr22.83 Million ≈ $2.46 Million |
-- |
About BioArctic AB (publ)
BioArctic AB (publ) develops biological drugs for patients with central nervous system disorders in Sweden. It engages in the research and development of innovative biological drugs, such as antibodies that address high unmet medical needs. The company's therapeutic areas encompass neurodegenerative disorders, such as Alzheimer's disease, Parkinson's disease, and other CNS diseases. In addition, … Read more